SOURCE: Pharming Group N.V.

November 01, 2007 13:07 ET

Pharming to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference

LEIDEN, NETHERLANDS--(Marketwire - November 1, 2007) - Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it will present at the Acumen BioFin Rodman & Renshaw Healthcare Conference (November 5-7, 2007) in New York.

Dr. Francis Pinto, Chief Executive Officer of Pharming, will present on Wednesday, November 7 at 1:40 pm Eastern Time. The presentation will be available on Pharming's website after the meeting.

The conference attendees include institutional investors from the United States and Europe. For further information on the Acumen BioFin Rodman & Renshaw Healthcare Conference, please visit www.rodmanandrenshaw.com/conferences.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with Novathera) and DNA repair (via its acquisition of DNage). Additional information is available on the Pharming website, www.pharming.com and on www.dnage.nl.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information

  • Contact:

    Carina Hamaker
    Investor Voice
    T: +31 (0)6 537 499 59
    T: +31 (0)71 52 47 400

    Julia Philips
    Financial Dynamics
    T: +44 (0)20 7269 7187
    T: +44 (0)7747 602 739

    Rein Strijker
    Pharming Group NV
    T: +31 (0)71 52 47 400

    Samir Singh
    Pharming Group NV
    T: +1 908 720 6224